Programme Thesis
The EIC Accelerator provides substantial non-dilutive grant and equity funding (up to €2.5M) to deep-tech startups and SMEs developing breakthrough innovations with high market potential and societal impact, particularly in health and sustainability. It exists to bridge the funding gap for high-risk, early-stage technologies that can scale globally, supporting ventures from pre-seed to commercialisation.
Selection Criteria
- Eligibility: Must be a for-profit SME (or startup) registered in an EU Member State or Horizon Europe associated country; single-company applications only; technology must be at least TRL 5-6 (validated in relevant environment).
- Scoring rubric: 1) Breakthrough/Deep Tech (30%) – novelty, scientific excellence, IP position; 2) Market Potential & Impact (30%) – scalability, EU strategic autonomy, societal benefit; 3) Team & Execution (20%) – founder expertise, business model, go-to-market plan; 4) Risk & Feasibility (20%) – technical, regulatory, financial risks and mitigation.
- Reviewer priorities: Clear path to commercialisation, strong IP strategy, alignment with EU Green Deal/Digital/Health priorities, evidence of customer traction or pilot partnerships, and a credible, diverse team.
Past Winners / Cohort Profiles
Past winners are typically deep-tech startups with a patented or patent-pending core technology, often spun out from universities or research institutes, with a founding team combining scientific and business expertise. Examples include: Graphenea (graphene production), Neuroelectrics (brain stimulation), and Biovotion (wearable health sensors). Archetype: a small team (2-5 people) with a PhD-level founder, a working prototype, initial IP, and a clear plan for EU-wide commercialisation.
Ideal Candidate Fingerprint
The platonic ideal applicant is an EU-registered deep-tech startup with a patented breakthrough in health or climate tech, at TRL 6+, a founding team with both scientific and entrepreneurial experience, early revenue or pilot contracts, and a scalable business model that aligns with EU strategic priorities. The technology should be disruptive, validated by independent data, and ready for market entry within 2-3 years.
Recommended Framing
Eniola should frame his CCT model and IMPRINT/TOPOLOGIX platforms as a breakthrough deep-tech solution for addiction and drug safety, with strong computational validation (Bayesian MCMC, 85.8% reduction in encoding probability) and a clear path to commercialisation via licensing to pharma or integration into clinical trial pipelines. He must emphasise the EU relevance (e.g., addressing opioid crisis, reducing drug development costs) and his provisional patent, while acknowledging the need to establish an EU-based SME (e.g., via ZYCO or a new spin-off) and secure early pilot partnerships to meet TRL requirements.
Watch Out
Eniola is not currently an EU resident or SME founder; the EIC Accelerator requires the applicant company to be registered in an EU Member State or Horizon Europe associated country. His technology is at an early stage (TRL 3-4, validated in silico but not in vivo or clinical), which may fall below the minimum TRL 5-6 threshold. He lacks a co-founder with business/commercialisation experience and has no revenue or pilot contracts. The programme is highly competitive and typically funds later-stage ventures.